In diabetes war, Novo Nordisk aims to break mold with new pill

• Novo Nordisk is in its final stage of trials for a new once-daily pill that stimulates insulin production, potentially replacing diabetics' need for daily insulin injections.
• The tablet's makeup requires those who take it to wait to eat after taking the pill and can cause nausea, raising questions about its practicality.
• Novo is also having difficulties with the pricing of the product, wondering where it will fit between the high prices of injectable insulin and lower prices of current oral drugs.